Upstream Bio says Phase 2 VALIANT trial shows verekitug cuts severe asthma exacerbation rate 56%
UPB•Phase 2 VALIANT results in severe asthma
Upstream Bio presented Phase 2 VALIANT trial results for verekitug in severe asthma in an oral session at ERS Congress 2026.
- Study showed fewer asthma flare-ups versus placebo, with improvements in breathing measures and airway inflammation indicators.
- Safety profile remained favorable, with no meaningful impact from immunogenicity on safety or efficacy.
- Phase 3 trials in severe asthma and CRSwNP remain slated to start in Q1 2027, testing a 400 mg quarterly regimen.
